ACM
CELG

Advent Capital Management’s Celgene Corp CELG Stock Holding History

Advent Capital Management’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-300
Closed -$12K – 371
2016
Q3 		$12K Buy
+300
New +$32.5K ﹤0.01% 466

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Advent Capital Management's CELG Position: Q2 2019 in Review

Advent Capital Management sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 28,000 shares — an estimated $2.64M sold.

Advent Capital Management first reported a position in CELG in Q2 2013 and held it in 5 quarters. The position peaked at $4.17M in Q4 2017. 1,288 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

  • Advent Capital Management reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
  • Advent Capital Management sold 28,000 Celgene Corp shares in Q2 2019, an estimated $2.64M.
  • Advent Capital Management first reported a position in Celgene Corp in Q2 2013 and held it in 5 quarters.
  • Advent Capital Management's Celgene Corp position peaked at $4.17M in Q4 2017.
  • 1,288 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on Advent Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.